annovisbio.comCrawled Oct 24, 2026
Open-label extension study allowing participants who complete the pivotal Phase 3 buntanetap trial in early Alzheimer's disease, and participants from prior Annovis AD trials, to receive buntanetap.
Annovis Bio's clinical pipeline, led by buntanetap, an investigational oral therapy in late-stage development for Alzheimer's and Parkinson's disease, with trial results and study details.
Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43.
Scientific posters and presentations on buntanetap from AAIC, CTAD, AD/PD and other conferences, including Phase 3 design, pharmacokinetics, and biomarker data.
Peer-reviewed publications on buntanetap, its mechanism of action, pharmacokinetics, and clinical results in Alzheimer's and Parkinson's disease.
Webcasts, interviews, and presentations from Annovis Bio leadership on buntanetap and the company's clinical programs.
Upcoming and past Annovis Bio investor events, conference presentations, and webcasts covering buntanetap and the company's Alzheimer's and Parkinson's programs.
Annovis Bio is a Phase 3 clinical-stage biotechnology company in Malvern, PA, developing buntanetap for neurodegenerative diseases. Meet our management team and board of directors.
Annovis Bio governance documents, board committees, and corporate policies.
Contact Annovis Bio investor relations at ir@annovisbio.com for shareholder and investor inquiries.
Contact Annovis Bio, 101 Lindenwood Drive, Suite 225, Malvern, PA 19355. Phone +1 (484) 875-3192, info@annovisbio.com.
Annovis Bio is a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily oral therapy for Alzheimer's and Parkinson's diseases.
Annovis Bio's policy on expanded access to its investigational drug buntanetap outside of clinical trials.
